Article Information
PubMed
Published By
History
- Received May 6, 2010
- Revision received June 28, 2010
- Accepted July 11, 2010
- First published September 1, 2010.
- Version of record published September 1, 2010.
Copyright & Usage
Copyright © 2010 the authors 0270-6474/10/3011735-10$15.00/0
Author Information
- Ghazaleh Sadri-Vakili1,
- Vidhya Kumaresan2,
- Heath D. Schmidt3,
- Katie R. Famous2,
- Prianka Chawla2,
- Fair M. Vassoler3,
- Ryan P. Overland1,
- Eva Xia1,
- Caroline E. Bass4,
- Ernest F. Terwilliger5,
- R. Christopher Pierce3, and
- Jang-Ho J. Cha1
- 1MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 02129-4404,
- 2Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118,
- 3Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104,
- 4Department of Pharmacology and Physiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, and
- 5Division of Experimental Medicine, Harvard Institutes of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115
- Correspondence should be addressed to Ghazaleh Sadri-Vakili, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129-4404. gsadrivakili{at}partners.org
Author contributions
Disclosures
- Received May 6, 2010.
- Revision received June 28, 2010.
- Accepted July 11, 2010.
-
This work was supported by National Institute on Drug Abuse Grants DA22339, DA18678 (R.C.P.), DA017543 and DA024763 (C.E.B.), and DA18333-02 (E.F.T.) and the Glendorn Foundation (J.-H.J.C.). K.R.F. was partially supported by National Institutes of Health (NIH) National Research Service Award (NRSA) F30 DA19304, as well as NIH Training Grant T32 GM008541-7. H.D.S. was also partially supported by NIH NRSA Award DA16824. We thank Dr. Caroline Benn for valuable discussions.
- Correspondence should be addressed to Ghazaleh Sadri-Vakili, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129-4404. gsadrivakili{at}partners.org
Online Impact